Wesper

Industry
Medical Devices & Equipment
Founded Year
2017
Headquarters
New York, USA
Employee Count
11

Key People

Assessment

Team
Aspect: First-time 10+ yrs
Summary: The leadership team comprises first-time entrepreneurs with over a decade of experience in relevant fields.

Amir Reuveny and Eyal Ronen, the founders, bring significant experience in technology and healthcare, which is advantageous for Wesper's growth.

Clinical Need
Aspect: Very Strong
Summary: There is a very strong clinical need for accessible and accurate sleep diagnostics.

With a growing number of individuals affected by sleep disorders, the demand for effective diagnostic tools is substantial.

Competition
Aspect: Somewhat crowded
Summary: The market has some competition but is not overly saturated.

While there are existing solutions, Wesper's unique approach offers a competitive edge.

Technical Challenge
Aspect: Moderate
Summary: The technical challenges are moderate and manageable.

Ensuring the reliability and accuracy of sleep diagnostic devices requires ongoing technical effort.

Patent
Aspect: Applied
Summary: Wesper has applied for patents to protect its technology.

Securing patents can provide a competitive advantage and protect Wesper's innovations.

Financing
Aspect: Well-funded
Summary: Wesper is well-funded with significant investment from reputable firms.

With $9.6 million raised in Series A funding, Wesper has the financial resources to advance its initiatives.

Regulatory
Aspect: 510k/PMA
Summary: Wesper has achieved FDA clearance for its device.

Obtaining FDA clearance is a significant milestone that facilitates market entry and builds consumer trust.

Opportunity Rollup

Odds of Success
4
Peak Market Share
5.7
Segment CAGR
6.9%
Market Segment
Sleep Diagnostic Devices
Market Sub Segment
Home Sleep Testing Devices
Year Post Launch Market Penetration (%)
1 0.29
2 0.86
3 2.00
4 3.99
5 5.70

Key Takeaway

Wesper is well-positioned in the growing sleep diagnostics market, leveraging strong leadership, innovative technology, and substantial funding to address a significant clinical need.